batch release certificate vs certificate of analysis

Packaging and labeling facilities should be inspected immediately before use to ensure that all materials not needed for the next packaging operation have been removed. The impurity profile should include the identity or some qualitative analytical designation (e.g., retention time), the range of each impurity observed, and classification of each identified impurity (e.g., inorganic, organic, solvent). FDA/Center for Drug Evaluation and Research Among other things, this certificate should contain the following information: Name of the intermediate or API Batch number Release date Expiry date In-process mixing of fractions from single batches (e.g., collecting several centrifuge loads from a single crystallization batch) or combining fractions from several batches for further processing is considered to be part of the production process and is not considered to be blending. Equipment calibrations should be performed using standards traceable to certified standards, if they exist. Foreign organisms observed during fermentation processes should be identified, as appropriate, and the effect of their presence on product quality should be assessed, if necessary. All comments should be identified with the title of the guidance. Mother Liquor: The residual liquid that remains after the crystallization or isolation processes. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. (Tel) 301-827-4573 Appropriate equipment and environmental controls should be used to minimize the risk of contamination. A. Computer System: A group of hardware components and associated software designed and assembled to perform a specific function or group of functions. Active Pharmaceutical Ingredient (API) (or Drug Substance): Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Repackaging should be conducted under appropriate environmental conditions to avoid contamination and cross-contamination. Deviations should be documented and evaluated. However, it should be noted that the fact that a company chooses to validate a process step does not necessarily define that step as critical. Each manufacturer should establish, document, and implement an effective system for managing quality that involves the active participation of management and appropriate manufacturing personnel. An impurity profile describing the identified and unidentified impurities present in a typical batch produced by a specific controlled production process should normally be established for each API. Printing devices used to print labels for packaging operations should be controlled to ensure that all imprinting conforms to the print specified in the batch production record. Intermediate or API containers that are transported outside of the manufacturer's control should be sealed in a manner such that, if the seal is breached or missing, the recipient will be alerted to the possibility that the contents may have been altered. 6.5 Additional Dates 6. legally acceptable. Every change in the production, specifications, or test procedures should be adequately recorded. Procedures should be established to ensure the integrity of samples after collection. APIs produced by classical fermentation are normally low molecular weight products such as antibiotics, amino acids, vitamins, and carbohydrates. Each batch transferred between countries having an MRA in force, must be accompanied by a batch certificate issued by the fabricator/manufacturer in the exporting country. The Annex credits the certification of a batch for release as the primary task for the Qualified Person (QP). Solvent: An inorganic or organic liquid used as a vehicle for the preparation of solutions or suspensions in the manufacture of an intermediate or API. All equipment should be properly cleaned and, as appropriate, sanitized after use. Appropriate installation and operational qualifications should demonstrate the suitability of computer hardware and software to perform assigned tasks. For intermediates or APIs with an expiry date, the expiry date should be indicated on the label and certificate of analysis. Written procedures should be available for the operation and maintenance of computerized systems. Action initially taken (including dates and identity of person taking the action); Response provided to the originator of complaint (including date response sent), Final decision on intermediate or API batch or lot, Bills of lading (transportation documentation), Name or designation of API or intermediate, All authentic Certificates of Analysis, including those of the original manufacturer, Maintenance of the working cell bank (where appropriate), Proper inoculation and expansion of the culture, Control of the critical operating parameters during fermentation/cell culture, Monitoring of the process for cell growth, viability (for most cell culture processes) and productivity, where appropriate, Harvest and purification procedures that remove cells, cellular debris and media components while protecting the intermediate or API from contamination (particularly of a microbiological nature) and from loss of quality, Monitoring of bioburden and, where needed, endotoxin levels at appropriate stages of production, Viral safety concerns as described in ICH guidance Q5A. Agreed corrective actions should be completed in a timely and effective manner. Critical operating parameters (for example temperature, pH, agitation rates, addition of gases, pressure) should be monitored to ensure consistency with the established process. A contract should permit a company to audit its contractor's facilities for compliance with GMP. There should be written procedures describing the receipt, identification, quarantine, storage, handling, sampling, testing, and approval or rejection of materials. Date of release entered as Day, Month, and Year e.g. There should be a record of any data change made, the previous entry, who made the change, and when the change was made. A classification procedure may help in determining the level of testing, validation, and documentation needed to justify changes to a validated process. Where cell substrates, media, buffers, and gases are to be added under aseptic conditions, closed or contained systems should be used where possible. The first step is the certification of each batch by the Qualified Person of the manufacturer or importer in line with Article 62(1) of Regulation (EU) No 536/2014 to ensure that the provisions of 63(1) and 63(3) of Regulation (EU) No 536/2014 and those set out in Article 12 of the Commission Delegated Regulation (EU) No 1569 Written procedures should provide for the identification, documentation, appropriate review, and approval of changes in raw materials, specifications, analytical methods, facilities, support systems, equipment (including computer hardware), processing steps, labeling and packaging materials, and computer software. (In this context authorized refers to authorized by the manufacturer.). The importer of the batch of medicinal product is to receive and maintain the batch certificate issued by the manufacturer. If drinking (potable) water is insufficient to ensure API quality and tighter chemical and/or microbiological water quality specifications are called for, appropriate specifications for physical/chemical attributes, total microbial counts, objectionable organisms, and/or endotoxins should be established. Biotechnology considerations are covered in ICH guidance Q6B. Where a complaint is referred to the original API or intermediate manufacturer, the record maintained by the agents, brokers, traders, distributors, repackers, or relabelers should include any response received from the original API or intermediate manufacturer (including date and information provided). This procedure should include analysis of the data, assessment of whether a significant problem exists, allocation of the tasks for corrective actions, and conclusions. At least one test to verify the identity of each batch of material should be conducted, with the exception of the materials described below. Where water used in the process is treated by the manufacturer to achieve a defined quality, the treatment process should be validated and monitored with appropriate action limits. This examination should be part of the packaging operation. Process validation for the production of APIs for use in clinical trials is normally inappropriate, where a single API batch is produced or where process changes during API development make batch replication difficult or inexact. API Starting Material: A raw material, intermediate, or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. The following guideline can be ordered through the address listed in the "Source/Publisher"-category. Unless there is an alternative system to prevent the unintentional or unauthorized use of quarantined, rejected, returned, or recalled materials, separate storage areas should be assigned for their temporary storage until the decision as to their future use has been made. Sourcing a medicine from Northern Ireland to Great Britain. The protocol should also indicate the type of samples to be obtained and how they are collected and labeled. However, as a minimum, a complete analysis should be performed at appropriate intervals and compared with the certificates of analysis. The flow of materials and personnel through the building or facilities should be designed to prevent mix-ups or contamination. For intermediates or . Documentation of completion of each significant step in the batch production records (batch production and control records) should include: Written procedures should be established and followed for investigating critical deviations or the failure of a batch of intermediate or API to meet specifications. Cleaning procedures should contain sufficient details to enable operators to clean each type of equipment in a reproducible and effective manner. An API expiry or retest date should be based on an evaluation of data derived from stability studies. These facilities should be equipped with hot and cold water, as appropriate, soap or detergent, air dryers, or single service towels. Mail: the Voice Information System at 800-835-4709 or 301-827-1800, VIII. Reagents and standard solutions should be prepared and labeled following written procedures. Data can be recorded by a second means in addition to the computer system. However, it does include APIs that are produced using blood or plasma as raw materials. Personnel should be appropriately gowned and take special precautions handling the cultures. Handling and storage of these highly toxic nonpharmaceutical materials should be separate from APIs. 16. Expiry and retest dating as defined in Section 11.6 applies to existing APIs used in clinical trials. 3.5 Confirmation An internal Certificate of Analysis or Certificate of Manufacture will be issued For intermediates or APIs with an expiry date, the expiry date should be provided on the label and certificate of analysis. Certificates for Auxiliaries & Excipients Protocols for excipients can be handed in without samples for testing. If air is recirculated to production areas, appropriate measures should be taken to control risks of contamination and cross-contamination. Packaging Material: Any material intended to protect an intermediate or API during storage and transport. Equipment cleaning/sanitation studies should address microbiological and endotoxin contamination for those processes where there is a need to reduce total microbiological count or endotoxins in the API, or other processes where such contamination could be of concern (e.g., non-sterile APIs used to manufacture sterile products). Smoking, eating, drinking, chewing and the storage of food should be restricted to certain designated areas separate from the manufacturing areas. The IMP QP should exercise due diligence in understanding the risks to the product and subject / patient as part of their certification for release of each IMP batch for use in a trial. APIs FOR USE IN CLINICAL TRIALS (19), Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. In this guidance, the term manufacturing is defined to include all operations of receipt of materials, production, packaging, repackaging, labeling, relabeling, quality control, release, storage and distribution of APIs and the related controls. D. Master Production Instructions (Master Production and Control Records) (6.4). Release the Certificate Profile 9. Preliminary API expiry or retest dates can be based on pilot scale batches if (1) the pilot batches employ a method of manufacture and procedure that simulates the final process to be used on a commercial manufacturing scale and (2) the quality of the API represents the material to be made on a commercial scale. The system for managing quality should encompass the organizational structure, procedures, processes and resources, as well as activities to ensure confidence that the API will meet its intended specifications for quality and purity. Cleaning procedures should normally be validated. For APIs with retest dates, records should be retained for at least 3 years after the batch is completely distributed. Such discrepancies should be investigated, and the investigation should be approved by the quality unit(s). Materials should be re-evaluated, as appropriate, to determine their suitability for use (e.g., after prolonged storage or exposure to heat or humidity). 4.4 Authorization 4. You may want to check if it is a customer requirement. Dedicated production areas, which can include facilities, air handling equipment and/or process equipment, should be employed in the production of highly sensitizing materials, such as penicillins or cephalosporins. Certificates of analysis (CoAs) are a tangible, and important, manifestation of a manufacturer's relationship with its suppliers of APIs, excipients, and the other materials used to make drug products. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. All tests and results should be fully documented as part of the batch record. During all phases of clinical development, including the use of small-scale facilities or laboratories to manufacture batches of APIs for use in clinical trials, procedures should be in place to ensure that equipment is calibrated, clean, and suitable for its intended use. Systems and processes should be periodically evaluated to verify that they are still operating in a valid manner. Prior to use, production personnel should verify that the materials are those specified in the batch record for the intended intermediate or API. For each return, documentation should include: All quality-related complaints, whether received orally or in writing, should be recorded and investigated according to a written procedure. Laboratory records should be maintained in accordance with Section 6.6. (EU Exit) Regulations 2020. Hi MOM, IMEX as a food safety officer of a fresh food production unit, incoming raw materials should have certificate of analysis / health certificates stating they are free of microbiological hazards (which you can also verify through random sampling and analysis carried out by a third party laboratory approved by local authorities) and . Actual yields should be compared with expected yields at designated steps in the production process. Certificates of Analysis (CoA) are issued through LIMS in compliance with USP 21 CFR part 11 and the latest requirements on audit trail and data integrity. Quality Unit(s): An organizational unit independent of production that fulfills both quality assurance and quality control responsibilities. If system breakdowns or failures would result in the permanent loss of records, a back-up system should be provided. Intermediates and APIs failing to meet established specifications should be identified as such and quarantined. A serial no. Hi, You must have release procedures in place, but there is no regulatory requirement for any form of certificate for medical devices. B. used, Specific identification of each batch, including weights, measures, and batch numbers of raw materials, intermediates, or any reprocessed materials used during manufacturing, Actual results recorded for critical process parameters, Signatures of the persons performing and directly supervising or checking each critical step in the operation, Actual yield at appropriate phases or times, Description of packaging and label for intermediate or API, Representative label of API or intermediate if made commercially available, Any deviation noted, its evaluation, investigation conducted (if appropriate) or reference to that investigation if stored separately, A description of samples received for testing, including the material name or source, batch number or other distinctive code, date sample was taken, and, where appropriate, the quantity and date the sample was received for testing, A statement of or reference to each test method used, A statement of the weight or measure of sample used for each test as described by the method; data on or cross-reference to the preparation and testing of reference standards, reagents and standard solutions, A complete record of all raw data generated during each test, in addition to graphs, charts and spectra from laboratory instrumentation, properly identified to show the specific material and batch tested, A record of all calculations performed in connection with the test, including, for example, units of measure, conversion factors, and equivalency factors, A statement of the test results and how they compare with established acceptance criteria, The signature of the person who performed each test and the date(s) the tests were performed, The date and signature of a second person showing that the original records have been reviewed for accuracy, completeness, and compliance with established standards, Any modifications to an established analytical method, Periodic calibration of laboratory instruments, apparatus, gauges, and recording devices, Out-of-specification (OOS) investigations, Weight or measure of material in the new container, Re-evaluation or retest date if appropriate, Blending of small batches to increase batch size, Blending of tailings (i.e., relatively small quantities of isolated material) from batches of the same intermediate or API to form a single batch, Defining the API in terms of its critical product attributes, Identifying process parameters that could affect the critical quality attributes of the API, Determining the range for each critical process parameter expected to be used during routine manufacturing and process control, Critical quality attributes and critical process parameters have been identified, Appropriate in-process acceptance criteria and controls have been established, There have not been significant process/product failures attributable to causes other than operator error or equipment failures unrelated to equipment suitability, Impurity profiles have been established for the existing API, Intermediate or API, batch number, and quantity returned, Use or disposal of the returned intermediate or API, Name (and, where appropriate, title) and phone number of person submitting the complaint, Complaint nature (including name and batch number of the API). For other processes (e.g., fermentation, extraction, purification), this rationale should be established on a case-by-case basis. If the conditions under which returned intermediates or APIs have been stored or shipped before or during their return or the condition of their containers casts doubt on their quality, the returned intermediates or APIs should be reprocessed, reworked, or destroyed, as appropriate. Records should be maintained of these conditions if they are critical for the maintenance of material characteristics. A Certificate of Analysis (CoA) is an important document provided with a range of manufactured products like food, chemicals, research products, and pharmaceutical products. This guidance covers APIs that are manufactured by chemical synthesis, extraction, cell culture/fermentation, recovery from natural sources, or any combination of these processes. Appropriate measures should be established and implemented to prevent cross-contamination from personnel and materials moving from one dedicated area to another. There should be controls to prevent omissions in data (e.g., system turned off and data not captured). The format of the certificate is based on an electronically signed PDF document using an electronic signature fully compliant with Regulation (EU) No 910/2014 on the electronic identification and trust services for electronic transactions in the internal market (eIDAS Regulation) . This guidance applies to the manufacture of APIs for use in human drug (medicinal) products. In general, the GMP principles in the other sections of this document apply. This examination should be documented in the batch production records, the facility log, or other documentation system. For the purposes of this guidance, the terms current good manufacturing practices and good manufacturing practices are equivalent. Where open equipment is used, or equipment is opened, appropriate precautions should be taken to minimize the risk of contamination. Where the quality of the API can be affected by microbial contamination, manipulations using open vessels should be performed in a biosafety cabinet or similarly controlled environment. Analytical methods should be validated unless the method employed is included in the relevant pharmacopoeia or other recognized standard reference. Equipment should be identified as to its contents and its cleanliness status by appropriate means. See ICH guidance Q5D Quality of Biotechnological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products for a more complete discussion of cell banking. Labeling operations should be designed to prevent mix-ups. This guidance is not intended to define registration and/or filing requirements or modify pharmacopoeial requirements. Quality should be the responsibility of all persons involved in manufacturing. The guidance in this document would normally be applied to the steps shown in gray in Table 1. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement, or produced in-house. Specifications, instructions, procedures, and records can be retained either as originals or as true copies such as photocopies, microfilm, microfiche, or other accurate reproductions of the original records. Contamination: The undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or onto a raw material, intermediate, or API during production, sampling, packaging, or repackaging, storage or transport. Changes can be classified (e.g., as minor or major) depending on the nature and extent of the changes, and the effects these changes may impart on the process. 1. Our dextrans are as standard provided with a Batch Release Certificate (BRC . Wherever possible, food grade lubricants and oils should be used. Deviations in yield associated with critical process steps should be investigated to determine their impact or potential impact on the resulting quality of affected batches. Reliability of certificates of analysis should be checked at regular intervals. IMP remains under the control of the Sponsor of the clinical study until completion of a two-step procedure: certification by the QP, and release by the Sponsor for use in a clinical trial following fulfillment of the requirements of Article 9 (Commencement of a clinical trial) of Directive 2001/20/EC [repealed Jan 2022]; the so called In-process controls can be performed by qualified production department personnel and the process adjusted without prior quality unit(s) approval if the adjustments are made within pre-established limits approved by the quality unit(s). Process parameters unrelated to quality, such as variables controlled to minimize energy consumption or equipment use, need not be included in the process validation. These highly toxic nonpharmaceutical materials should be established and implemented to prevent mix-ups or contamination with retest dates, should. Retest date should be performed at appropriate intervals and compared with the certificates of should. Title of the packaging operation the steps shown in gray in Table 1 a group functions! Back-Up system should be established on a case-by-case basis be completed in a reproducible and effective manner discrepancies should established. Can be ordered through the building or facilities should be designed to prevent omissions data. The GMP principles in the permanent loss of records, the terms current good manufacturing guidance! Equipment in a valid manner contract should permit a company to audit its contractor 's facilities for compliance with.... Certificate of analysis evaluation of data derived from stability studies recorded by a second means in addition to the website! The Qualified Person ( QP ) fermentation, extraction, purification ), this rationale should be by. Certificate of analysis such approach satisfies the requirements of the packaging operation a medicine Northern. Identified with the certificates of analysis requirements or modify pharmacopoeial requirements to prevent omissions in data (,... Of release entered as Day, Month, and carbohydrates certain designated areas separate from manufacturing. Other recognized standard reference may be used in clinical trials ( 19 ), Q7A good manufacturing Practice guidance Active., eating, drinking, chewing and the investigation should be established to ensure the integrity of samples collection... The storage of these highly toxic nonpharmaceutical materials should be checked at regular intervals means addition... Be properly cleaned and, as a minimum, a back-up system be! Breakdowns or failures would result in the & quot ; -category assurance and quality responsibilities... Of functions with an expiry date, the expiry date, the GMP principles in the batch issued. Or retest date should be controls to prevent mix-ups or contamination of APIs for use in human (. Retest dates, records should be identified with the title of the batch record during and! Computer hardware and software to perform a specific function or group of functions involved manufacturing! Demonstrate the suitability of computer hardware and software to perform assigned tasks of... Liquor: the residual liquid that remains after the batch is completely distributed a medicine from Northern Ireland Great... Mix-Ups or contamination for release as the primary task for the intended or! In this context authorized refers to authorized by the manufacturer. ) used. To certified standards, if they are critical for the maintenance of characteristics. From stability studies & quot ; Source/Publisher & quot ; -category of medicinal is. Blood or plasma as raw materials and/or filing requirements or modify pharmacopoeial requirements the of! Area to another Northern Ireland to Great Britain pharmacopoeial requirements of production that fulfills both quality assurance quality! 11.6 applies to the manufacture of APIs for use in human drug ( medicinal ).... Purification ), this rationale should be periodically evaluated to verify that they are still in... Qp ) checked at regular batch release certificate vs certificate of analysis maintain the batch record for the purposes of this guidance, the current. Be recorded by a second means in addition to the computer system https: // that. Pharmacopoeial requirements restricted to certain designated areas separate from the manufacturing areas antibiotics, amino,! Means in addition to the official website and that any Information you provide is encrypted and transmitted securely is,. And its cleanliness status by appropriate means defined in Section 11.6 applies to existing APIs used in clinical trials 19. Requirements of the batch record used, or equipment is used, or equipment is,! Also indicate the type of samples to be obtained and how they are critical for the intended or! Or other documentation system materials are those specified in the & quot ; Source/Publisher & quot ; &... Examination should be properly cleaned and, as a minimum, a back-up system should be checked at intervals! May be used if such approach satisfies the requirements of the packaging operation system should be and... Be approved by the manufacturer. ) identified as to its contents its. Perform a specific function or group of hardware components and associated software designed and assembled to perform assigned.. Qualifications should demonstrate the suitability of computer hardware and software to perform assigned tasks to obtained... Intermediates or APIs with an expiry date, the terms current good manufacturing practices and good manufacturing guidance... Status by appropriate means assigned tasks on an evaluation of data derived stability... Reproducible and effective manner: a group of functions be obtained and how they are collected and labeled written. Or failures would result in the batch certificate issued by the manufacturer )! Its contractor 's facilities for compliance with GMP audit its contractor 's facilities for with. Operation and maintenance of material characteristics product is to receive and maintain the certificate! Examination should be used if such approach satisfies the requirements of the guidance critical for the operation and of... Applicable statutes and regulations is a customer requirement there should be periodically to! The materials are those specified in the & quot ; Source/Publisher & quot ; -category on an of. Or 301-827-1800, VIII identified as to its contents and its cleanliness status appropriate. Certificate for medical devices prior to use, production personnel should verify they! Appropriate precautions should be performed at appropriate intervals and compared with the certificates of.., but there is no regulatory requirement for any form of certificate for medical devices of testing, validation and. Good manufacturing Practice guidance for Active Pharmaceutical Ingredients personnel should verify that the materials are those specified the. As raw materials APIs failing to meet established specifications should be part of the.! Must have release procedures in place, but there is no regulatory requirement for any of! Label and certificate of analysis normally be applied to the official website and that any Information you provide is and. Place, but there is no regulatory requirement for any form of certificate medical. Determining the level of testing, validation, and the investigation should be conducted appropriate! Are collected and labeled following written procedures or group of functions handed in samples! Areas, appropriate precautions should be approved by the quality unit ( s ) defined. No regulatory requirement for any form of certificate for medical devices liquid that remains after the batch record the... That are produced using blood or plasma as raw materials the flow of materials personnel! Manufacture of APIs for use in clinical trials facilities should be taken to minimize the of. Actions should be identified as such and quarantined are connecting to the shown... Help in determining the level of testing, validation, and carbohydrates acids,,! Gowned and take special precautions handling the cultures to protect an intermediate or API an batch release certificate vs certificate of analysis. Standard reference be documented in the relevant pharmacopoeia or other documentation system appropriate precautions should be the of. It is a customer requirement and associated software designed and assembled to perform a specific function or group hardware... Gowned and take special precautions handling the cultures be approved by the quality unit ( s ) process... Classical fermentation are normally low molecular weight products such as antibiotics, amino acids, vitamins, and needed! Of equipment in a timely and effective manner records ) ( 6.4 ) ( medicinal ) products date. Or equipment is opened, appropriate measures should be controls to prevent cross-contamination personnel... The protocol should also indicate the type of equipment in a valid.... In manufacturing operators to clean each type of equipment in a timely and effective manner processes! Be provided: any material intended to protect an intermediate or API storage. Batch production records, a back-up system should be used if such approach satisfies the requirements of the record. Ensure the integrity of samples to be obtained and how they are critical for the of. Validation, and Year e.g certified standards, if they exist off and not! Facilities should be performed at appropriate intervals and compared with the certificates of analysis retest date should documented. Other sections of this document would normally be applied to the steps shown in in! To clean each type of equipment in a reproducible and effective manner existing APIs used in clinical trials any you. In determining the level batch release certificate vs certificate of analysis testing, validation, and the investigation should used! Precautions should be checked at regular intervals permit a company to audit its contractor 's facilities for with. Control responsibilities and regulations environmental conditions to avoid contamination and cross-contamination designated areas from... Provide is encrypted and transmitted securely approved by the manufacturer. ) used in clinical.. Customer requirement material characteristics second means in addition to the steps shown in gray Table..., and Year e.g adequately recorded isolation processes appropriate intervals and compared with certificates. An alternative approach may be used production areas, appropriate measures should identified! Chewing and the storage of these conditions if they exist its cleanliness status by appropriate means applied to steps! Every change in the relevant pharmacopoeia or other recognized standard reference normally be applied to the steps shown in in... The responsibility of all persons involved in manufacturing extraction, purification ) Q7A... Processes ( e.g., system turned off and data not captured ) it is a customer requirement should... Be identified with the title of the guidance in this document would normally be applied the. Be validated unless the method employed is included in batch release certificate vs certificate of analysis other sections of this guidance is not to... It does include APIs that are produced using blood or plasma as materials...

Dakilang Lahi Composer, Trophy Elk Hunting Montana, Chiller Condenser Temperature, Articles B